What question did this study set out to answer?

To assess current methodologies, biological obstacles, and computational strategies for identifying tumor neoantigens in cancer immunotherapy.

June 12, 2025Frontiers in ImmunologyOpen Access

Advances and challenges in neoantigen prediction for cancer immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

YZYi Zhang TCTingting Chen XLXiong Li

Discussion

Member takes

Overview

Review reveals multi-omics integration enhances neoantigen prediction accuracy in tumor immunotherapy, highlighting hurdles from tumor heterogeneity and immune evasion.

Key Points

To assess current methodologies, biological obstacles, and computational strategies for identifying tumor neoantigens in cancer immunotherapy.
Reviewed immunogenomic profiling workflows utilizing next-generation sequencing to pinpoint tumor-specific mutations.
Evaluated immunopeptidomic strategies employing mass spectrometry to identify MHC-bound peptide presentations.
Coupling immunogenomic mutation data with immunopeptidomics qualitative profiling enhances neoantigen prediction accuracy compared with genomic analysis alone.
Identification efficiency faces ongoing constraints driven by dynamic tumor heterogeneity, diverse human leukocyte antigen (HLA) alleles, and active tumor immune evasion mechanisms.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/6a015368e92f4a033c856587 https://doi.org/10.3389/fimmu.2025.1617654

View Full Paper

Ask AI

Bookmark

June 12, 2025Frontiers in ImmunologyOpen Access

Advances and challenges in neoantigen prediction for cancer immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

YZYi Zhang TCTingting Chen XLXiong Li

Discussion

Member takes

Overview

Review reveals multi-omics integration enhances neoantigen prediction accuracy in tumor immunotherapy, highlighting hurdles from tumor heterogeneity and immune evasion.

Key Points

To assess current methodologies, biological obstacles, and computational strategies for identifying tumor neoantigens in cancer immunotherapy.
Reviewed immunogenomic profiling workflows utilizing next-generation sequencing to pinpoint tumor-specific mutations.
Evaluated immunopeptidomic strategies employing mass spectrometry to identify MHC-bound peptide presentations.
Coupling immunogenomic mutation data with immunopeptidomics qualitative profiling enhances neoantigen prediction accuracy compared with genomic analysis alone.
Identification efficiency faces ongoing constraints driven by dynamic tumor heterogeneity, diverse human leukocyte antigen (HLA) alleles, and active tumor immune evasion mechanisms.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/6a015368e92f4a033c856587 https://doi.org/10.3389/fimmu.2025.1617654

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark